These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 30418192)

  • 21. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
    Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P
    J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis.
    Passiglia F; Bronte G; Bazan V; Natoli C; Rizzo S; Galvano A; Listì A; Cicero G; Rolfo C; Santini D; Russo A
    Oncotarget; 2016 Apr; 7(15):19738-47. PubMed ID: 26918451
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer.
    Remon J; Chaput N; Planchard D
    Curr Opin Oncol; 2016 Mar; 28(2):122-9. PubMed ID: 26756384
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer.
    Tsao MS; Le Teuff G; Shepherd FA; Landais C; Hainaut P; Filipits M; Pirker R; Le Chevalier T; Graziano S; Kratze R; Soria JC; Pignon JP; Seymour L; Brambilla E
    Ann Oncol; 2017 Apr; 28(4):882-889. PubMed ID: 28137741
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real world data in the era of Immune Checkpoint Inhibitors (ICIs): Increasing evidence and future applications in lung cancer.
    Pasello G; Pavan A; Attili I; Bortolami A; Bonanno L; Menis J; Conte P; Guarneri V
    Cancer Treat Rev; 2020 Jul; 87():102031. PubMed ID: 32446182
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune checkpoint inhibitors in advanced non-small cell lung cancer.
    Assi HI; Kamphorst AO; Moukalled NM; Ramalingam SS
    Cancer; 2018 Jan; 124(2):248-261. PubMed ID: 29211297
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
    Ng TL; Liu Y; Dimou A; Patil T; Aisner DL; Dong Z; Jiang T; Su C; Wu C; Ren S; Zhou C; Camidge DR
    Cancer; 2019 Apr; 125(7):1038-1049. PubMed ID: 30548240
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC).
    Yoneda K; Imanishi N; Ichiki Y; Tanaka F
    J UOEH; 2018; 40(2):173-189. PubMed ID: 29925736
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune Checkpoint Inhibitors for Patients With Advanced Non-Small-Cell Lung Cancer: A Systematic Review.
    Ellis PM; Vella ET; Ung YC
    Clin Lung Cancer; 2017 Sep; 18(5):444-459.e1. PubMed ID: 28416123
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor expression and usefulness as a biomarker of programmed death ligand 1 in advanced non-small cell lung cancer patients with preexisting interstitial lung disease.
    Shibaki R; Murakami S; Matsumoto Y; Goto Y; Kanda S; Horinouchi H; Fujiwara Y; Yamamoto N; Motoi N; Kusumoto M; Yamamoto N; Ohe Y
    Med Oncol; 2019 Apr; 36(6):49. PubMed ID: 31030326
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Companion and Complementary Diagnostics-Focus on PD-L1 Expression Assays for PD-1/PD-L1 Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
    Hersom M; Jørgensen JT
    Ther Drug Monit; 2018 Feb; 40(1):9-16. PubMed ID: 29084031
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune checkpoint inhibitors in first-line therapy of advanced non-small cell lung cancer.
    Remon J; Besse B
    Curr Opin Oncol; 2017 Mar; 29(2):97-104. PubMed ID: 28059852
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunotherapy combinations in advanced nonsmall cell lung cancer.
    Pirker R
    Curr Opin Oncol; 2021 Jan; 33(1):73-79. PubMed ID: 33186185
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1.
    Smith KN; Llosa NJ; Cottrell TR; Siegel N; Fan H; Suri P; Chan HY; Guo H; Oke T; Awan AH; Verde F; Danilova L; Anagnostou V; Tam AJ; Luber BS; Bartlett BR; Aulakh LK; Sidhom JW; Zhu Q; Sears CL; Cope L; Sharfman WH; Thompson ED; Riemer J; Marrone KA; Naidoo J; Velculescu VE; Forde PM; Vogelstein B; Kinzler KW; Papadopoulos N; Durham JN; Wang H; Le DT; Justesen S; Taube JM; Diaz LA; Brahmer JR; Pardoll DM; Anders RA; Housseau F
    J Immunother Cancer; 2019 Feb; 7(1):40. PubMed ID: 30744692
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nivolumab for treating non-small cell lung cancer.
    Guibert N; Mazières J
    Expert Opin Biol Ther; 2015; 15(12):1789-97. PubMed ID: 26574148
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).
    Hsu PC; Jablons DM; Yang CT; You L
    Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387256
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer.
    Chen Y; Liu Q; Chen Z; Wang Y; Yang W; Hu Y; Han W; Zeng H; Ma H; Dai J; Zhang H
    J Exp Clin Cancer Res; 2019 May; 38(1):193. PubMed ID: 31088500
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Predictive biomarkers of efficacy of checkpoint blockade inhibitors in cancer treatment].
    Duruisseaux M; Lize-Dufranc C; Badoual C; Bibeau F
    Ann Pathol; 2017 Feb; 37(1):46-54. PubMed ID: 28131419
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Predictive biomarkers for immune checkpoint inhibitors in non-small-cell lung cancer].
    Fu MJ; Zhou JY
    Zhonghua Jie He He Hu Xi Za Zhi; 2020 Feb; 43(2):87-91. PubMed ID: 32062877
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
    Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
    Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.